Cortexyme and Lilly remind investors that Alzheimer’s failures happen
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
AC Immune claims a tau win in Alzheimer’s
But mixed data and a previous failure provide reasons to be cautious.
AC Immune backs alpha-synuclein despite recent setbacks
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
A busy year ahead for Parkinson’s disease
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
Roche buys into Prothena... kind of
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
